Figure 3.

Gapmer ASO 15 improves anxiety-like behavior and abnormal locomotor functions of hTDP-43 mice in the open-field test

(A–F) WT and hTDP-43 mice were injected with either control ASO C2 or ASO 15 (200 μg) into the cerebral ventricles at 6 weeks of age, and analyzed using the open-field test at 3, 5, and 7 months of age. Tracking data of the movement of representative mice at 3 months of age are shown in (A). Time spent in the center region (B), total travel distance (C), and total movement number (F) were measured, and average travel distance (D) and duration (E) per movement were calculated and shown as bar graphs. Bar graph data are presented as the mean ± SEM of 17–22 animals in each group. Dots represent values from individual mice. Statistical analyses were performed to assess differences among groups at each time point by two-way repeated-measures ANOVA followed by the Tukey multiple comparisons test (B, C, and F) and one-way ANOVA followed by the Tukey multiple comparisons test (D and E) (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; n.s., not significant). In (C), ∗p < 0.05: ASO C2-injected hTDP-43 mice versus ASO C2-injected WT mice; ^#p < 0.05: ASO 15-injected hTDP-43 mice versus ASO C2-injected hTDP-43 mice.